IS7639A - Bensósýruafleiður sem stillar PPAR alfa og gamma - Google Patents

Bensósýruafleiður sem stillar PPAR alfa og gamma

Info

Publication number
IS7639A
IS7639A IS7639A IS7639A IS7639A IS 7639 A IS7639 A IS 7639A IS 7639 A IS7639 A IS 7639A IS 7639 A IS7639 A IS 7639A IS 7639 A IS7639 A IS 7639A
Authority
IS
Iceland
Prior art keywords
gamma
adjust
benzoic acid
acid derivatives
ppar alpha
Prior art date
Application number
IS7639A
Other languages
English (en)
Inventor
Li Lanna
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7639A publication Critical patent/IS7639A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS7639A 2002-06-20 2005-01-12 Bensósýruafleiður sem stillar PPAR alfa og gamma IS7639A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201937A SE0201937D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
PCT/GB2003/002598 WO2004000295A1 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma

Publications (1)

Publication Number Publication Date
IS7639A true IS7639A (is) 2005-01-12

Family

ID=20288295

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7639A IS7639A (is) 2002-06-20 2005-01-12 Bensósýruafleiður sem stillar PPAR alfa og gamma

Country Status (21)

Country Link
US (1) US7521461B2 (is)
EP (1) EP1517680A1 (is)
JP (1) JP4327085B2 (is)
KR (1) KR20050014014A (is)
CN (1) CN100400512C (is)
AR (1) AR040332A1 (is)
AU (1) AU2003240101B2 (is)
BR (1) BR0311840A (is)
CA (1) CA2490687A1 (is)
IL (1) IL165672A0 (is)
IS (1) IS7639A (is)
MX (1) MXPA04012694A (is)
NO (1) NO20045222L (is)
NZ (1) NZ536972A (is)
PL (1) PL375078A1 (is)
RU (1) RU2339613C2 (is)
SE (1) SE0201937D0 (is)
TW (1) TW200403209A (is)
UA (1) UA77527C2 (is)
WO (1) WO2004000295A1 (is)
ZA (1) ZA200409690B (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
CA2489834C (en) 2002-06-20 2006-10-03 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
BRPI0414536A (pt) * 2003-09-17 2006-11-07 Novartis Ag compostos orgánicos
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7816405B2 (en) * 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
CA2621406A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
JP2007234800A (ja) 2006-02-28 2007-09-13 Tdk Corp 電子部品及びその製造方法
JP5564251B2 (ja) * 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ, エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008128126A1 (en) 2007-04-11 2008-10-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN107441097A (zh) 2010-04-16 2017-12-08 阿西纳斯公司 用于预防和治疗癌症的组合物以及方法
EP2736329A4 (en) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US9926273B2 (en) 2012-08-30 2018-03-27 Athenex, Inc. Composition and methods for modulating a kinase cascade
WO2019105234A1 (zh) * 2017-11-30 2019-06-06 四川科伦博泰生物医药股份有限公司 芳香族化合物及其药物组合物和用途
EP4232425A4 (en) 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
DK148576A (da) * 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
US5334753A (en) * 1992-03-12 1994-08-02 Rhone-Poulenc Agriculture Ltd Processes for preparing ortho-substituted benzoic acids
DE19615263A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
DE19616948C1 (de) 1996-04-27 1997-11-27 Wagner Gmbh J Schneidwerkzeug, insbesondere Astschere
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
AU9696198A (en) * 1997-10-17 1999-05-10 Aventis Pharmaceuticals Products Inc. Therapeutic uses of quinoline derivatives
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
NZ515087A (en) 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6509374B2 (en) * 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
TW200403209A (en) 2004-03-01
JP2006502105A (ja) 2006-01-19
UA77527C2 (en) 2006-12-15
NZ536972A (en) 2006-06-30
WO2004000295A1 (en) 2003-12-31
ZA200409690B (en) 2005-10-11
CA2490687A1 (en) 2003-12-31
EP1517680A1 (en) 2005-03-30
RU2339613C2 (ru) 2008-11-27
AU2003240101B2 (en) 2006-09-21
RU2004135542A (ru) 2005-08-10
US20050267149A1 (en) 2005-12-01
AU2003240101A1 (en) 2004-01-06
BR0311840A (pt) 2005-03-15
CN100400512C (zh) 2008-07-09
NO20045222L (no) 2005-01-19
PL375078A1 (en) 2005-11-14
CN1662230A (zh) 2005-08-31
JP4327085B2 (ja) 2009-09-09
SE0201937D0 (sv) 2002-06-20
IL165672A0 (en) 2006-01-15
MXPA04012694A (es) 2005-03-23
KR20050014014A (ko) 2005-02-05
AR040332A1 (es) 2005-03-30
US7521461B2 (en) 2009-04-21

Similar Documents

Publication Publication Date Title
NO20031777L (no) Benzosyreisononylester og dens anvendelse
IS7434A (is) N-amínóasetýl-pýrrólídín-2-karbónítríl og notkun þeirra sem DDP-IV tálma
DK1501815T3 (da) Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
NO20041872L (no) Esterforbindelser og medisinsk anvendelse derav
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
IS7575A (is) Própíónsýruafleiður og notkun þeirra sem HPPAR virkjar
IS7470A (is) Kínólínafleiður og notkun þeirra sem 5-HT6 tengla
IS7749A (is) Pýrimídínafleiður og notkun þeirra sem CB2 beina
NO20031775L (no) Oppblåsbar pakning og fremgangsmåte
IS8392A (is) Heterósýklískir hindrar MEK og notkun þeirra
DE60317702D1 (de) Orthopädische zange mit ratsche
IS7926A (is) 4-útskipt bensímídasól og notkun þeirra sem magasýruseytishemla
NO20034669D0 (no) Karboksylsyrederivat og salt derav
EP1557594A4 (en) OIL RING
IS7711A (is) Ný oxasól og þíasól efnasambönd sem umbreytingar vaxtaþátta (TGF) hindrar
DK1534248T3 (da) Lasofoxifentablet og dens overtræk
PL375078A1 (en) Benzoic acid derivatives as modulators of ppar alpha and gamma
DE60330269D1 (de) Piperazinyl- und diazapanylbenzamide und-benzothioamide
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
ITPD20020133A1 (it) Letto particolarmente articolato
DE60327447D1 (de) Pflaster
NO20032183D0 (no) Histon-deacetylase inhibitor og anvendelse derav
DK1589938T3 (da) Mundplejesammensætninger og fremgangsmåder hertil
DK1537091T3 (da) Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
IS7829A (is) Nýjar 1,4-díazabísýklóalkan-afleiður, framleiðslaþeirra og notkun